DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

Status unconfirmed

Conditions studied: Psychoses

In brief

The purpose of this study is to assess patients treated with the antipsychotics aripiprazole (Abilify®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), or ziprasidone (Geodon®) and to identify genetic variations more commonly found in individuals who develop diabetic metabolic signs and symptoms, which include changes in blood lipids, blood glucose, blood pressure, and body weight.

Key facts

Study ID

NCT00752960

Run by

Genomas, Inc

People needed

1000

Starts

2007-01-01

Expected to finish

2009-12-01

Last updated by the study team

2008-09-16

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• receiving atypical antipsychotic therapy (olanzapine, aripiprazole, quetiapine, risperidone, or ziprasidone) for 3 months
• who have taken >50% of the prescribed dose for the last month.

You may not qualify if…

• none

Where it is running

• Hartford Hospital Institute of Living — Hartford, Connecticut, United States (enrolling)
• University of Kentucky — Lexington, Kentucky, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.